MA32230B1 - Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one - Google Patents

Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one

Info

Publication number
MA32230B1
MA32230B1 MA33250A MA33250A MA32230B1 MA 32230 B1 MA32230 B1 MA 32230B1 MA 33250 A MA33250 A MA 33250A MA 33250 A MA33250 A MA 33250A MA 32230 B1 MA32230 B1 MA 32230B1
Authority
MA
Morocco
Prior art keywords
forms
amino
methylpiperazine
benzimidazole
quinoline
Prior art date
Application number
MA33250A
Other languages
Arabic (ar)
English (en)
Inventor
Danielle Giron
Walter Hammerschmidt
Philippe Piechon
Johanne Polasek
Andreas Schreiner
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32230(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32230B1 publication Critical patent/MA32230B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formes cristallines ou des polymorphes de lactates de 4-amino-5-fluoro-3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl] quinolin-2(1h)-one, ainsi que leurs procédés de préparation, des compositions pharmaceutiques les comprenant et des procédés de traitement les utilisant.
MA33250A 2008-03-19 2010-10-15 Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one MA32230B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19
PCT/EP2009/053222 WO2009115562A2 (fr) 2008-03-19 2009-03-18 Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one

Publications (1)

Publication Number Publication Date
MA32230B1 true MA32230B1 (fr) 2011-04-01

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33250A MA32230B1 (fr) 2008-03-19 2010-10-15 Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one

Country Status (24)

Country Link
US (1) US8563556B2 (fr)
EP (1) EP2257544B1 (fr)
JP (1) JP2011515370A (fr)
KR (1) KR20100137517A (fr)
CN (1) CN101970425B (fr)
AR (1) AR070924A1 (fr)
AU (1) AU2009227003B2 (fr)
BR (1) BRPI0909762A2 (fr)
CA (1) CA2718076A1 (fr)
CL (1) CL2009000651A1 (fr)
CO (1) CO6321253A2 (fr)
EC (1) ECSP10010555A (fr)
IL (1) IL208020A0 (fr)
MA (1) MA32230B1 (fr)
MX (1) MX2010010152A (fr)
MY (1) MY150554A (fr)
NZ (2) NZ600887A (fr)
PE (1) PE20091628A1 (fr)
PH (2) PH12012502568A1 (fr)
RU (1) RU2497820C2 (fr)
SG (1) SG188919A1 (fr)
TW (1) TWI426072B (fr)
WO (1) WO2009115562A2 (fr)
ZA (1) ZA201006263B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
ES2707625T3 (es) 2010-04-16 2019-04-04 Novartis Ag Compuesto orgánico para su utilización en el tratamiento del cáncer de hígado
NZ602807A (en) 2010-04-16 2014-02-28 Novartis Ag 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
WO2012125812A1 (fr) 2011-03-17 2012-09-20 Novartis Ag Fgfr et ses ligands utilisés comme biomarqueurs du cancer du sein chez des sujets rh positifs
BR112013029246A2 (pt) 2011-05-19 2017-02-14 Novartis Ag 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
JP2014526506A (ja) 2011-09-15 2014-10-06 ノバルティス アーゲー 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
US20150202203A1 (en) 2012-07-11 2015-07-23 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
WO2014058785A1 (fr) 2012-10-10 2014-04-17 Novartis Ag Polythérapie
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (fr) 2014-01-31 2019-03-27 Novartis AG Molécules d'anticorps anti-tim-3 et leurs utilisations
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016100882A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Polythérapies
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3370768B9 (fr) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Anticorps se liant spécifiquement à pd-1 et leurs utilisations
WO2017106656A1 (fr) 2015-12-17 2017-06-22 Novartis Ag Molécules d'anticorps anti-pd-1 et leurs utilisations
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304344B6 (cs) * 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (fr) * 2002-08-23 2010-11-09 Chiron Corporation Quinolinones de benzimidazole et leurs utilisations
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
AU2003290699B2 (en) 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
KR101387985B1 (ko) * 2005-01-27 2014-04-25 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 전이 종양의 치료
MX2007014782A (es) * 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
RU2433826C2 (ru) * 2005-11-29 2011-11-20 Новартис Аг Композиции хинолинонов
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme

Also Published As

Publication number Publication date
NZ587829A (en) 2012-08-31
KR20100137517A (ko) 2010-12-30
WO2009115562A2 (fr) 2009-09-24
EP2257544A2 (fr) 2010-12-08
WO2009115562A3 (fr) 2009-11-26
AU2009227003A1 (en) 2009-09-24
AR070924A1 (es) 2010-05-12
PH12012502569A1 (en) 2015-09-21
MX2010010152A (es) 2010-10-25
RU2497820C2 (ru) 2013-11-10
CN101970425A (zh) 2011-02-09
TW201000463A (en) 2010-01-01
AU2009227003B2 (en) 2013-03-14
CO6321253A2 (es) 2011-09-20
ECSP10010555A (es) 2010-11-30
HK1147492A1 (en) 2011-08-12
IL208020A0 (en) 2010-12-30
NZ600887A (en) 2013-10-25
CN101970425B (zh) 2014-04-16
CA2718076A1 (fr) 2009-09-24
CL2009000651A1 (es) 2010-07-19
JP2011515370A (ja) 2011-05-19
EP2257544B1 (fr) 2014-12-03
ZA201006263B (en) 2011-05-25
TWI426072B (zh) 2014-02-11
US8563556B2 (en) 2013-10-22
US20110021536A1 (en) 2011-01-27
RU2010142396A (ru) 2012-04-27
PH12012502568A1 (en) 2014-10-27
PE20091628A1 (es) 2009-11-19
MY150554A (en) 2014-01-30
BRPI0909762A2 (pt) 2018-04-03
SG188919A1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA43116B1 (fr) Ditosylate de valbénazine et polymorphes associés
MA30967B1 (fr) Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
TN2011000626A1 (en) 1h-imidazo[4,5-c]quinolinone derivatives
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
EA201100032A1 (ru) Соединения пиридина
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
EP2450046A4 (fr) Composition à visée médicale pour le traitement de la bronchite et sa préparation
MA29532B1 (fr) Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
WO2011151722A3 (fr) Méthodes et compositions de traitement pharmaceutique par voie orale
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
EP2134712A4 (fr) Aspartate de l'acide 1-cyclopropyl-6-fluoro-7-(8-méthoxyimino-2,6-diaza- spiro [3.4]oct-6-yl)-4-oxo-1,4-dihydro- [1,8] naphthyridine-3-carboxylique, leurs méthodes de préparation, et préparations pharmaceutiques antimicrobiennes les contenant
MA37524A1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions